Rhythm Pharmaceuticals Achievements and Q3 Financial Results

Rhythm Pharmaceuticals
Rhythm Pharmaceuticals (RYTM) reported financial results and provided a business update for the third quarter ended September 30, 2020. The firm develops treatments of rare genetic disorders of obesity. The FDA has accepted the firm's filed New Drug Application (NDA) for it's product, setmelanotide, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.